Advertisement

Advertisement

Hematologic Malignancies
COVID-19

Aggressive Supportive Treatment for COVID-19 May Be Needed in Patients With Hematologic Cancers

New research underscores the need for aggressive support of patients hospitalized with blood cancer and COVID-19, according to data presented at the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition. Two studies of one of the largest data sets of patients with blood cancer...

COVID-19

Are Patients Undergoing Active Cancer Treatment More Likely to Believe COVID-19 Misinformation?

Patients with cancer undergoing active treatment were more likely to believe misinformation related to COVID-19 than those without a history of cancer, according to a new study published by Guidry et al in Patient Education and Counseling. “These findings help us better understand the threat of...

Lung Cancer
COVID-19

Study Finds Patients With Lung Cancer Demonstrated Psychological Resilience in the Face of the COVID-19 Pandemic

Far from being hobbled by fears of COVID-19, patients with lung cancer actually showed less depression and anxiety during the pandemic than their healthy peers, according to results from a new study by Arrato et al published in JNCCN–Journal of the National Comprehensive Cancer Network. Researchers ...

COVID-19

AMA: CDC Quarantine and Isolation Guidance Is Confusing, Counterproductive

“Nearly 2 years into this pandemic, with Omicron cases surging across the country, the American people should be able to count on the Centers for Disease Control and Prevention (CDC) for timely, accurate, clear guidance to protect themselves, their loved ones, and their communities. Instead, the...

COVID-19

AACR Releases Report on the Impact of COVID-19 on Cancer Research and Patient Care

On February 9, the American Association for Cancer Research (AACR) released the AACR Report on the Impact of COVID-19 on Cancer Research and Patient Care. According to findings contained within the report, patients with cancer are not only at an increased risk for developing severe COVID-19, but...

COVID-19

Adverse Event Rates After Two Doses of mRNA COVID-19 Vaccine in Patients With vs Without Cancer

New research published by Shulman et al in JNCCN—Journal of the National Comprehensive Cancer Network confirmed that mRNA vaccines for COVID-19 are just as safe for people with cancer as they are for cancer-free individuals. Researchers from a single institution tracked short-term side effects from ...

Lung Cancer
COVID-19

TERAVOLT Study Identifies Seven Factors That Increase Mortality Risk for Patients With Lung Cancer Infected With COVID-19

The risk of death for patients with SARS–CoV-2 infection and thoracic cancer is based on seven major determinants, according to research published by Alessio Cortellini, MD, in the Journal of Thoracic Oncology. TERAVOLT Data The researchers analyzed data from the Thoracic Cancers International...

Issues in Oncology
COVID-19

Challenges for Oncologists as They Reach Retirement Age

In 2014, The ASCO Post spoke with Mark J. Clemons, MB BS, BMedSci, MSc, MD, FRCP, FRCPC, of Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada, about the retirement challenges faced by many oncologists. With market demand expected to exceed supply of oncologists soon, it is clear retirement is...

COVID-19

FDA Approves Second COVID-19 Vaccine

On January 31, the U.S. Food and Drug Administration (FDA) approved a second COVID-19 vaccine, which has been known as the Moderna COVID-19 vaccine, for the prevention of COVID-19 in individuals aged 18 years and older; the approved vaccine will be marketed as Spikevax. “The FDA’s approval of [the...

COVID-19
Issues in Oncology

Health Groups Make Recommendations to Strengthen the U.S. Drug Supply Chain During the Pandemic and Beyond

ASCO—along with the American Medical Association, the American Society of Anesthesiologists, the American Society of Health-System Pharmacists, and the United States Pharmacopeia—released a series of policy and marketplace recommendations to address the significant challenges in our nation’s drug...

Hematologic Malignancies
COVID-19

Aggressive Supportive Treatment for COVID-19 May Be Needed in Patients With Hematologic Cancers

New research underscores the need for aggressive support of patients hospitalized with blood cancer and COVID-19, according to data presented at the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition. Two studies of one of the largest data sets of patients with blood cancer...

COVID-19

Immunogenicity of COVID-19 BNT162b2 mRNA Vaccine Booster in Patients With Cancer Receiving Active Treatment

In an Israeli single-institution study reported in The Lancet Oncology, Ligumsky et al found that a booster dose of the SARS–CoV-2 Pfizer-BioNTech BNT162b2 mRNA vaccine given in August or September 2021 was immunogenic in patients receiving active cancer treatment. Antibody levels prior to and...

COVID-19

FDA Shortens Interval for Booster Dose of Moderna COVID-19 Vaccine to 5 Months

On January 7, the U.S. Food and Drug Administration (FDA) amended the emergency use authorization (EUA) for the Moderna COVID-19 vaccine to shorten the time between the completion of a primary series of the vaccine and a booster dose to at least 5 months for individuals aged 18 years and older....

COVID-19

NCCN Updates Recommendations on COVID-19 Vaccination and Preexposure Prophylaxis

Today, the National Comprehensive Cancer Network® (NCCN®) published significant updates to the expert consensus recommendations on vaccination and preexposure prophylaxis of COVID-19 for people with cancer. The NCCN Advisory Committee on COVID-19 Vaccination and Preexposure Prophylaxis meets...

COVID-19

Study Finds Fully Vaccinated Patients With Cancer and Breakthrough COVID-19 Infection Remain at High Risk for Severe Outcomes

A study evaluating the clinical characteristics and outcomes of fully vaccinated patients with cancer who had breakthrough COVID-19 infections indicated they remained at high risk for hospitalization and death. The report, published by Schmidt et al in Annals of Oncology, showed that fully...

multiple myeloma
covid-19

Nikhil C. Munshi, MD, PhD, on COVID-19 Vaccine Effectiveness in Patients With Multiple Myeloma

Nikhil C. Munshi, MD, PhD, of Dana-Farber Cancer Institute, discusses the findings from a large nationwide Veterans Affairs study, which showed that, for patients with multiple myeloma, the effectiveness of the COVID-19 vaccine is reduced, likely due to patients’ immunosuppression. Dr. Munshi describes what next steps should be taken (Abstract 400).

Solid Tumors
Hematologic Malignancies
COVID-19

Study Finds Third COVID-19 Vaccine Dose Effectively Boosts Immunity for Patients With Solid Tumors

Nearly 100% of patients with solid tumors have antibodies effective against the SARS–CoV-2 delta variant after a third dose of COVID-19 vaccine, according to results published as a correspondence by Fendler et al in Cancer Cell. The new findings also highlight a proportion of patients with blood...

COVID-19

FDA Takes Multiple Actions to Expand Use of Pfizer-BioNTech COVID-19 Vaccine

On January 3, the U.S. Food and Drug Administration (FDA) amended the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine to expand the use of a single booster dose to include use in individuals aged 12 to 15 years; shorten the time between the completion of primary...

COVID-19

Positive Practice Changes After the COVID-19 Pandemic: From the Advanced Practice Provider Perspective

The COVID-19 pandemic may have changed some aspects of health care forever. At the 2021 JADPRO Live Virtual event, a panel discussion focused on how several cancer centers faced challenges, and what changes the participants view as positive.1 JADPRO Live is an annual educational conference for...

COVID-19

European OnCovid Registry Analysis of Time-Dependent COVID-19 Mortality in Patients With Cancer

As reported in JAMA Oncology by researchers from the OnCovid Study Group, an updated analysis of the European OnCovid registry indicated that mortality due to COVID-19 infection has decreased over time for patients with cancer during the pandemic. Study Details The study included real-world data on ...

Hematologic Malignancies
COVID-19

Antibody Response to COVID-19 Vaccination in Patients With Myeloid and Lymphoid Neoplasms

According to a German study by Rotterdam et al presented at the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract 218), about 15% of people with blood cancers and other blood disorders had no vaccination-related antibodies after receiving a COVID-19 vaccine....

Hematologic Malignancies
COVID-19

ASH RC COVID-19 Registry for Hematology: Risk Factors for Hospitalization and Death Among Patients With Hematologic Malignancies Infected With COVID-19

Patients with blood cancers, particularly those with more advanced disease, are at increased risk for serious COVID-19 outcomes, including an elevated chance of severe illness or death from infection, according to an analysis of more than 1,000 patients in the ASH Research Collaborative (RC)...

Myelodysplastic Syndromes
Leukemia
COVID-19

Antibody Response to Second Dose of mRNA COVID-19 Vaccine in Patients With AML and MDS

In one of the largest studies to date of the antibody response to vaccination against COVID-19 in people who had been treated for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), patients responded well to two doses of the Moderna mRNA vaccine and saw a pronounced increase in levels ...

COVID-19

COVID-19 Vaccine Requirements for Medicare, Medicaid Facilities, and Employers of 100 or More Staff Released

On November 4, 2021, the Centers for Medicare & Medicaid Services (CMS) issued an interim final rule requiring COVID-19 vaccination of eligible staff at health-care facilities that participate in the Medicare and Medicaid programs, and the Occupational Safety and Health Administration (OSHA)...

Issues in Oncology
COVID-19

Telemedicine Use Among U.S. Patients With Newly Diagnosed Cancer: Impact of Socioeconomic Status

In a study reported in a research letter in JAMA Oncology, Katz et al found that higher socioeconomic status was associated with greater use of telemedicine among patients with newly diagnosed cancers in the United States between January and August 2020. As stated by the investigators, “The...

COVID-19

COVID-19 Infection After SARS–CoV-2 Messenger RNA Vaccination in Patients With Cancer

In a study reported in JAMA Oncology, Wu et al found that vaccination with SARS–CoV-2 messenger RNA vaccines reduced the incidence of COVID-19 infection vs no vaccination in Veterans Affairs (VA) patients with cancer. Vaccine effectiveness varied according to time between last systemic therapy and...

Multiple Myeloma
COVID-19

Fully Vaccinated Patients With Multiple Myeloma: Rates of SARS–CoV-2 Breakthrough Infection and Hospitalization

In a U.S. cohort study reported in JAMA Network Open, Wang et al found that fully vaccinated patients with multiple myeloma were at increased risk of breakthrough SARS–CoV-2 infection, and that those with breakthrough infection were more likely to be hospitalized vs fully vaccinated persons without ...

Multiple Myeloma
COVID-19

COVID-19 Vaccination: Patients With Multiple Myeloma May Lack T-Cell Response

Patients with multiple myeloma lacking an antibody response to COVID-19 vaccination may also fail to mount a T-cell response, researchers from the Icahn School of Medicine at Mount Sinai have reported. This scenario seemed to be most common among patients actively treated with anti-CD38 and...

Solid Tumors
COVID-19

Response to Third Dose of SARS–CoV-2 BNT162b2 mRNA Vaccine in Patients With Solid Tumors Undergoing Active Treatment

In a single-institution Israeli study reported in a research letter in JAMA Oncology, Rottenberg et al found that a booster dose of the SARS–CoV-2 BNT162b2 mRNA resulted in increased spike protein antibody titers in patients with solid tumors undergoing active treatment. Study Details The study...

immunotherapy
covid-19

Jeffrey Weber, MD, PhD, on Coronavirus, Cancer, and Immunotherapy: Navigating Clinical Trials and Treatment

Jeffrey Weber, MD, PhD, of NYU Langone Medical Center, offers his perspective on the impact of the COVID-19 pandemic on oncology care and cancer clinical trials, as clinicians strive to provide optimal treatment to patients while reducing their risk of contracting the coronavirus. The steep decline in trial enrollment has recovered, with many of the changes in how research was conducted as a result of the pandemic still in place and improving the process going forward.

immunotherapy
covid-19

Hannah E. Dzimitrowicz, MD, on COVID-19 Vaccination in Patients With Cancer Receiving Immune Checkpoint Inhibitors

Hannah E. Dzimitrowicz, MD, of Duke Cancer Center, discusses study results showing that in patients with melanoma and renal cell cancer receiving immune checkpoint inhibitor therapy, the COVID-19 vaccination appears to be well tolerated and safe. A higher rate of post-vaccination symptoms reported in these patients is likely related to more frequent visits compared with controls (Abstract 625).

COVID-19

Effect of the COVID-19 Pandemic on Cancer Imaging

Significant decreases in computed tomography (CT) imaging for cancer persisted even after the peak of the COVID-19 pandemic in 2020—delaying diagnosis and treatment and raising the possibility of more advanced cancers and poorer outcomes for patients, according to a study presented at the...

Immunotherapy
COVID-19

Response to SARS–CoV-2 mRNA Vaccination in Patients With B-Cell Depletion Associated With CAR T-Cell Therapy

In a small single-institution study reported in a research letter in JAMA Oncology, Parvathaneni et al found that SARS–CoV-2 mRNA vaccination produced antibody responses in nearly half—and CD4 T-cell responses in more than half—of patients with B-cell depletion due to treatment with...

COVID-19

Mortality Risk in Patients With Cancer and SARS–CoV-2 Higher Among Older Patients With B-Cell Malignancies and Those Who Previously or Currently Smoke

A recent study published in JCO Oncology Practice found that patients with certain cancers have a higher mortality risk than those with other cancer types if they have contracted the novel coronavirus (SARS–CoV-2).1 Specifically, older patients with B-cell malignancies who acquire SARS–CoV-2 who...

COVID-19

COVID-19 Resources for People With Cancer

ASCO has compiled a number of resources to help people with cancer navigate COVID-19. Coronavirus and COVID-19: What People With Cancer Need to Know Cases of COVID-19 have arisen all over the world. Here’s what people with cancer and cancer survivors need to know about the disease. Available at...

COVID-19

FDA Expands Eligibility for COVID-19 Vaccine Boosters

On November 19, the U.S. Food and Drug Administration (FDA) amended the emergency use authorizations (EUA) for both the Moderna and Pfizer-BioNTech COVID-19 vaccines authorizing use of a single booster dose for all individuals aged 18 years and older after completion of primary vaccination with any ...

COVID-19
Solid Tumors

Immunogenicity of COVID-19 Vaccination in Patients Receiving Systemic Therapy for Solid Tumors

In a Dutch study (VOICE) reported in The Lancet Oncology, Sjoukje F. Oosting, MD, and colleagues found that the mRNA-1273 (Moderna) COVID-19 vaccine produced adequate antibody responses in a majority of patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumors, with...

Lung Cancer
COVID-19

French Study Finds COVID-19 Vaccine Effective in Patients With Lung Cancer

In a new study published by Gounant et al in the Journal of Thoracic Oncology, researchers from France showed that SARS–CoV-2 vaccines are safe and effective in patients with thoracic cancer, most of whom are immunized after two doses. A third shot given to 11% of patients with persistent low...

COVID-19

Immunogenicity of SARS–CoV-2 Vaccines in Patients With Cancer

In a single-institution prospective cohort study (CANVAX Cohort Study) reported in the Journal of Clinical Oncology, Naranbhai and colleagues assessed the immunogenicity of SARS–CoV-2 vaccines in patients with cancer. They found that immunogenicity varied among vaccines and that both antibody...

COVID-19

Study Examines COVID-19 Outcomes in Pediatric Patients With Cancer

Most children and adolescents with cancer have mild COVID-19 disease and make a full recovery, a new study by Haeusler et al in the European Journal of Cancer has found. But pediatric patients with cancer and underlying health conditions, severe infections, and low white blood cell counts were...

Solid Tumors
COVID-19

Many Patients With Solid Tumors Mount an Adequate Response to SARS–CoV-2 Vaccine, Dutch Study Reports

Individuals with solid tumors had an appropriate, protective immune response to vaccination against SARS–CoV-2, at least with the mRNA-1273 vaccine, and side effects were no more common than in the general population, according to a large Dutch study.1 The study was reported during the European...

Hematologic Malignancies
COVID-19

Study Examines Breakthrough COVID-19 Infection in Vaccinated Patients With Hematologic Cancers

People with blood cancers are at a higher risk than healthy individuals for severe infection with COVID-19; furthermore, research suggests that they do not always achieve optimal protection from vaccination. A new study published by Pagano et al in the journal Blood—the first to report on...

COVID-19

COVID-19 Sequelae Prevalence, Risk Factors, and Outcomes in Patients With Cancer

In a retrospective European study reported in The Lancet Oncology, David J. Pinato, PhD, and colleagues found that among patients with cancer who recovered from COVID-19 infection, a substantial proportion have sequelae that can affect survival and oncologic outcomes. Among patients on systemic...

COVID-19

Study Finds Patients Infected With COVID-19 Who Underwent Recent Cancer Treatment Are at Higher Risk of Adverse Outcomes

In a cohort study reported in JAMA Oncology, Mariana Chavez-MacGregor, MD, MSc, and colleagues found that patients with cancer infected with COVID-19 had poorer outcomes vs patients without cancer if they had received recent cancer treatment. Patients with cancer who had not received recent...

COVID-19

Characteristics, Effects, and Outcomes of SARS–CoV-2 Infection in Pediatric Patients With Cancer

In an article published in the Journal of Clinical Oncology, Emily E. Johnston, MD, MS, and colleagues detailed characteristics, effects on cancer treatment, and outcomes of SARS–CoV-2 infection in pediatric patients with cancer based on data from The Pediatric Oncology COVID-19 Case Report...

Lung Cancer
COVID-19

Study Evaluates Virtual vs In-Person Visits and Access to Lung Cancer Screening

Findings from a novel telemedicine effort to screen patients for lung cancer screening during the COVID-19 pandemic show that virtual single-visit screenings may be just as effective as single-visit screenings done in person, according to a study presented by Magarinos et al at the American College ...

COVID-19

FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Children Aged 5 Through 11 Years

On October 29, the U.S. Food and Drug Administration (FDA) authorized the emergency use of the Pfizer-BioNTech COVID-19 vaccine for the prevention of COVID-19 to include children aged 5 through 11 years. The authorization was based on the FDA’s thorough and transparent evaluation of the data that...

Multiple Myeloma
COVID-19

Patients With Multiple Myeloma May Lack T-Cell Responses to COVID-19 Vaccination

Patients with multiple myeloma lacking an antibody response to COVID-19 vaccine may also fail to mount a T-cell response, according to research from the Icahn School of Medicine at Mount Sinai. Concerningly, this scenario was most common among patients actively treated with anti-CD38 and...

Hematologic Malignancies
COVID-19

Patients With Hematologic Malignancies: How Robust Is Their Immunity to SARS–CoV-2?

A large study from the United Kingdom has taken a deep dive into SARS–CoV-2 in the setting of cancer, yielding both concerning and encouraging findings about natural and vaccine-induced immunity. The study was presented at the Presidential Symposium during the European Society for Medical Oncology...

Issues in Oncology
COVID-19

Study Examines Opinions on Telemedicine Among Patients Undergoing Radiotherapy

New research published by Shaverdian et al in JNCCN—Journal of the National Comprehensive Cancer Network assessed patient satisfaction and preferences associated with telemedicine. Researchers found 45% of people with cancer undergoing radiotherapy preferred telemedicine, whereas 34% preferred...

Advertisement

Advertisement

Advertisement